LA
PCVX icon

Lee Ainslie’s Vaxcyte PCVX Stock Holding History

Lee Ainslie’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.8M Buy
1,613,242
+235,504
+17% +$12.8M 0.83% 39
2026
Q1 		$80.1M Buy
1,377,738
+23,501
+2% +$1.28M 0.92% 35
2025
Q4 		$62.5M Buy
1,354,237
+64,670
+5% +$2.89M 0.67% 38
2025
Q3 		$46.5M Sell
1,289,567
-21,038
-2% -$697K 0.62% 43
2025
Q2 		$42.6M Buy
1,310,605
+102,512
+8% +$3.36M 0.64% 43
2025
Q1 		$45.6M Buy
1,208,093
+6,195
+0.5% +$495K 0.81% 43
2024
Q4 		$98.4M Buy
1,201,898
+225,649
+23% +$22.4M 1.77% 23
2024
Q3 		$112M Buy
976,249
+288,341
+42% +$26M 2.18% 17
2024
Q2 		$51.9M Buy
687,908
+332,777
+94% +$22.7M 0.99% 32
2024
Q1 		$24.3M Buy
+355,131
New +$24.6M 0.46% 52

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Lee Ainslie's PCVX Position: Q2 2026 in Review

Lee Ainslie increased its Vaxcyte (PCVX) stake by 17% in Q2 2026, buying an estimated $12.8M and bringing the position to 1,613,242 shares worth $93.8M. The position accounts for 0.83% of the portfolio, ranked #39.

Lee Ainslie first reported a position in PCVX in Q1 2024 and has held it in 10 quarters since. The position peaked at $112M in Q3 2024. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Lee Ainslie held 1,613,242 shares of Vaxcyte worth $93.8M as of Q2 2026.
  • Lee Ainslie bought 235,504 Vaxcyte shares in Q2 2026, an estimated $12.8M.
  • Vaxcyte made up 0.83% of Lee Ainslie's portfolio in Q2 2026, its #39 holding.
  • Lee Ainslie first reported a position in Vaxcyte in Q1 2024 and has held it in 10 quarters since.
  • Lee Ainslie's Vaxcyte position peaked at $112M in Q3 2024.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.